UK markets closed

Fresenius SE & Co. KGaA (FRE.DE)

XETRA - XETRA Delayed price. Currency in EUR
Add to watchlist
37.81-0.35 (-0.92%)
At close: 5:35PM CET

Fresenius SE & Co. KGaA

Else-Kröner-Strasse 1
Bad Homburg vor der Höhe 61352
49 6172 608 2487

IndustryMedical Care Facilities
Full-time employees309,114

Key executives

NameTitlePayExercisedYear born
Mr. Stephan SturmCEO, Pres & Chairman of Management Board - Fresenius Management SE3.49MN/A1963
Ms. Rachel Clare EmpeyCFO & Member of Management Board - Fresenius Management SE1.61MN/A1976
Dr. Francesco De MeoMember of Management Board - Fresenius Management SE2.4MN/A1963
Dr. Ernst WastlerMember of Management Board - Fresenius Management SE1.43MN/A1958
Mr. Mats Christer HenrikssonMember of Management Board - Fresenius Management SE2.36MN/A1967
Mr. Rice PowellMember of Management Board - Fresenius Management SE4.63MN/A1955
Mr. Markus GeorgiSr. VP of Investor RelationsN/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment specializes in the therapy and care of chronically and critically ill patients. This segment offers IV drugs, including intravenously administered generic anesthetics, analgesics, anti-infectives, and drugs for the treatment of oncological and other critical diseases; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; infusion and nutrition pumps, as well as consumables; and products that are used in the collection and processing of blood components, as well as in transfusion medicine and cell therapy. As of December 31, 2019, this segment operated 86 hospitals, approximately 125 outpatient clinics, and 8 prevention centers. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. Fresenius SE & Co. KGaA has a strategic partnership with Humacyte Inc. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

Corporate governance

Fresenius SE & Co. KGaA’s ISS governance QualityScore as of 1 November 2019 is 8. The pillar scores are Audit: 10; Board: 6; Shareholder rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.